Skip to content
Back to explorer
Printable monograph

Adrenolytic

Mitotane

Lysodren · MTT

Adrenolytic · approved 1970 · 6 citations

Up to date· through 2025
Fairly sourced5/9 · 5 signals
  • Met: 6 citations
  • Not met: 12+ references
  • Not met: Accrued over 10+ years (span: 8y)
  • Met: Beyond single case reports
  • Met: High-impact journal
  • Met: Landmark reference
  • Met: Current through 2025
  • Not met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

Adrenolytic for adrenocortical carcinoma; renal risk is indirect — adrenal insufficiency drives hyponatremia and prerenal azotemia, compounded by cisplatin in EDP-M.

Moderateestablished
Advanced/metastatic adrenocortical carcinomaAdjuvant therapy after resection of adrenocortical carcinoma (high recurrence risk)Component of the EDP-M regimen (etoposide, doxorubicin, cisplatin + mitotane) for advanced diseaseControl of cortisol hypersecretion in Cushing syndrome (off-label)

Kidney summary

Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.

Renal dosing
Avoid or contraindicated in impairment
Not recommended in severe renal impairment; in mild-moderate impairment monitor mitotane plasma levels frequently and modify the dose as needed
The atlas summary, paraphrased — not label text. Verbatim label excerpt. Dosing section.
Hemodialysis
Not removed by hemodialysis
Not dialyzable (highly lipophilic, tissue-distributed); dosing is guided by plasma-level monitoring and tolerability, with no standardized renal dose reduction.
The atlas summary. Full prose in the Dialyzability section.
FDA boxed warning
Yes
Label: Lysodren, Mar 2026. Not necessarily about the kidney. FDA label section.
§01

Signature kidney injury

Signature lesion

Intrinsic mitotane nephrotoxicity is not characteristically quantified. Clinically important renal events are indirect (adrenal insufficiency-related electrolyte/volume disturbance) or attributable to co-administered cisplatin in EDP-M; incidence not reliably enumerated for mitotane alone.Source: Turla et al., Endocrine 2022 (indirect: hypoadrenalism + cisplatin in EDP-M)

Onset & rechallenge

Time to injurySubacute (~1–6 weeks)

Adrenal insufficiency and its electrolyte/volume consequences accrue over weeks of adrenolytic therapy (with any cisplatin-associated AKI in EDP-M occurring acutely within days of cycles).

Distilled from: “Adrenal insufficiency and its electrolyte/volume consequences develop over weeks of therapy as adrenolytic effect accrues; cisplatin-associated AKI in EDP-M is acute, within days of chemotherapy cycles.”

Long-term outlook & early detection

Renal recovery

Usually reversible

Renal events with mitotane are indirect and correctable rather than a fixed lesion: adrenal-insufficiency-driven hyponatremia, volume depletion and prerenal azotemia resolve with adequate glucocorticoid/mineralocorticoid replacement and restoration of volume and electrolytes, and any AKI during EDP-M is managed as cisplatin-associated injury. There is no established direct mitotane tubular toxicity to leave permanent damage.PMID 35567656 (opens PubMed in a new tab)

Early-detection biomarkers

  • Serum sodium (hyponatremia) — electrolyte / prerenal signature from mitotane-induced hypoadrenalism (cortisol and, importantly, aldosterone deficiency). Mitotane's renal risk is indirect and endocrine: it induces adrenal insufficiency with mineralocorticoid (aldosterone) deficit, so a falling serum sodium is the earliest bedside marker of the volume/electrolyte derangement and prerenal azotemia that follows under-replacement. A systematic review documented aldosterone insufficiency in 36.8% of mitotane-treated patients, grounding sodium as the drug-specific early signal.PMID 34638485 (opens PubMed in a new tab)
  • Plasma renin activity / serum aldosterone — onset of mitotane-induced mineralocorticoid deficiency that precedes hyponatremia, volume depletion and prerenal azotemia. Because roughly a third of mitotane-treated patients require mineralocorticoid replacement, rising plasma renin activity with an inadequate aldosterone response flags evolving mineralocorticoid deficiency before frank electrolyte/volume-driven renal compromise, prompting fludrocortisone repletion. Drug-specific endocrine marker, not a tubular-injury assay.PMID 32937772 (opens PubMed in a new tab)

Distilled from the agent's cited literature — educational, not a substitute for the primary sources.

Recovery across agents
§02

Renal toxicities, ranked

This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

  1. Electrolyte Disturbance#1 · Signaturequalitative — no citable incidence

    Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).

  2. Prerenal / Hemodynamic AKISecondaryqualitative — no citable incidence

    Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.

§03

Kidney injury

Mechanism of kidney injury

Mitotane has no well-established direct tubular nephrotoxicity; its renal relevance is indirect and endocrine. By inducing adrenal insufficiency (hypoadrenalism) and accelerating cortisol/aldosterone metabolism, it can produce hyponatremia, volume depletion, and prerenal azotemia, particularly when glucocorticoid/mineralocorticoid replacement is inadequate. Persistent nausea, vomiting, and asthenia signal hypoadrenalism and worsen prerenal physiology. Mitotane is given within the EDP-M regimen alongside cisplatin, a directly nephrotoxic agent — so AKI in these patients is frequently attributable to cisplatin and to the volume/electrolyte derangements of adrenal insufficiency rather than to mitotane itself.

Clinical presentation

Hyponatremia, hypotension, fatigue, nausea/vomiting and prerenal azotemia in the setting of under-replaced adrenal insufficiency; superimposed cisplatin-type AKI when EDP-M is used. Frank intrinsic kidney injury directly from mitotane is not a typical presentation.

Management

Treat the underlying adrenal insufficiency with adequate steroid replacement and restore volume/electrolytes; correct hyponatremia per cause and rate-safe guidelines. For AKI during EDP-M, manage as cisplatin-associated injury (hydration, nephrotoxin avoidance, dose/schedule modification). Mitotane itself is rarely the direct culprit for kidney injury.Lesion-level management framework

Risk factors

  • Inadequate glucocorticoid/mineralocorticoid replacement
  • Concurrent cisplatin (EDP-M regimen)
  • Pre-existing mild renal impairment
  • Poor performance status with poor oral intake
  • Persistent vomiting causing volume depletion

Prevention

  • Mandatory glucocorticoid (and mineralocorticoid as needed) replacement to prevent adrenal crisis and resultant prerenal/electrolyte derangement
  • Aggressive antiemesis and maintenance of hydration
  • For patients with mild renal impairment receiving EDP-M, consider 24-hour continuous-infusion cisplatin to reduce nephrotoxicity risk
  • Replace sodium to correct depletion, guided by regular volume-status assessment
Anticancer mechanism· how it treats cancer

Adrenolytic agent (an o,p'-DDD isomer related to the insecticide DDT) that is selectively cytotoxic to adrenocortical cells, causing focal degeneration of the zona fasciculata and reticularis; it suppresses cortisol production and exerts direct antitumor activity against adrenocortical carcinoma, while also accelerating peripheral steroid metabolism.

Note · The kidney threat with mitotane is endocrine and regimen-driven (hypoadrenalism + cisplatin), not direct tubular toxicity. Mitotane plasma level monitoring (target therapeutic window) is also standard for efficacy/toxicity balance.
§04

Clinical depth

Renal dose adjustment

Mitotane has no standardized CrCl-band renal dose reduction; dosing is guided by plasma-level monitoring and tolerability. Per the FDA label, mitotane is not recommended in severe renal impairment; in mild-to-moderate impairment, monitor plasma levels frequently and modify the dose as needed. In EDP-M with mild renal impairment, cisplatin scheduling (e.g., continuous infusion) is also modified to mitigate nephrotoxicity.

Dialyzability & ESKD dosing

Dialyzability not characterized/clinically relevant; mitotane is highly lipophilic and tissue-distributed, making dialysis removal unlikely to be useful.

Differential diagnosis

In a mitotane-treated patient with AKI/hyponatremia, distinguish (1) adrenal insufficiency with prerenal azotemia/volume depletion, (2) cisplatin-induced tubular injury from EDP-M, and (3) SIADH or other causes — rather than attributing injury to direct mitotane tubular toxicity.

Monitoring

  • Serum sodium and other electrolytes
  • Volume/blood pressure status and signs of adrenal insufficiency
  • Renal function (especially during cisplatin-containing cycles)
  • Mitotane plasma concentrations (therapeutic monitoring)
  • Cortisol/ACTH and adequacy of steroid replacement

Key trials & series

  • Turla et al. (Endocrine 2022): supportive-care guidance for the EDP-M regimen, explicitly addressing mitotane-induced hypoadrenalism and management of patients with mild renal impairment (cisplatin scheduling)
  • EDP-M established as standard first-line cytotoxic regimen for advanced adrenocortical carcinoma
Where it strikes· nephron segments & injury signatures

Nephron segments

Distal Tubule / Collecting Duct

Fine-tuning of Na, K, Mg, acid & water

Vasculature / Endothelium

Glomerular & peritubular capillaries

§05

References

6 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.

Evidence accrual

6 references · 2017–2025 · 1 since 2023
202017: 1 citation2020: 1 citation2021: 2 citations2022: 1 citation2025: 1 citation201720202025

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

  1. 1.Metabolic and Endocrine Toxicities of Mitotane: A Systematic Review.Bianchini M, Puliani G, et al · Cancers (Basel) · 2021 · PMID 34638485Systematic review documenting mitotane-induced adrenal insufficiency, including mineralocorticoid (aldosterone) insufficiency in 36.8%, supporting the indirect endocrine mechanism (cortisol/aldosterone disruption to electrolyte disturbance) rather than direct tubular nephrotoxicity.
  2. 2.Unwanted Hormonal and Metabolic Effects of Postoperative Adjuvant Mitotane Treatment for Adrenocortical Cancer.Basile V, Puglisi S, et al · Cancers (Basel) · 2020 · PMID 32937772Documents that ~32% of mitotane-treated patients required mineralocorticoid replacement, evidencing induction of adrenal insufficiency with aldosterone deficit and consequent electrolyte disturbance.
  3. 3.Mitotane-Induced Endocrine Alterations in Children with Adrenocortical Carcinoma: Clinical Implications from a 20-Year Retrospective Study.Tuli G, Munarin J, et al · Children (Basel) · 2025 · PMID 40868483Documents that mitotane-treated pediatric ACC patients developed adrenal insufficiency requiring glucocorticoid and, in some, mineralocorticoid replacement, supporting the indirect endocrine mechanism of altered cortisol/aldosterone and consequent electrolyte disturbance.
  4. 4.Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen.Turla A et al. · Endocrine · 2022 · PMID 35567656Directly addresses management of mitotane-induced hypoadrenalism and of patients with mild renal impairment on EDP-M (including continuous-infusion cisplatin to reduce nephrotoxicity).
  5. 5.Conventional Chemotherapy Nephrotoxicity.Gupta S et al. · Adv Chronic Kidney Dis · 2021 · PMID 35190107Reviews cisplatin nephrotoxicity and chemotherapy-associated electrolyte disturbances/hyponatremia — context for the cisplatin and electrolyte risks accompanying mitotane in EDP-M.
  6. 6.LandmarkAcute Kidney Injury in Patients with Cancer.Rosner MH et al. · N Engl J Med · 2017 · PMID 28467867Onconephrology overview supporting the framing of prerenal/electrolyte (indirect) injury versus direct tubular toxicity in this setting.
FDA label — boxed warning & renal dosing· boxed warning · renal impairment

Quoted verbatim from this agent's current FDA label (Mar 2026) — not paraphrased or interpreted. Full label on DailyMed .

Boxed warning

WARNING: ADRENAL CRISIS IN THE SETTING OF SHOCK, SEVERE TRAUMA OR INFECTION Patients treated with LYSODREN are at increased risk for developing adrenal crisis in the setting of shock, severe trauma or infection that may lead to death. If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. Monitor patients closely for infections and instruct patients to contact their physician immediately if injury, infection, or any other concomitant illness occurs [see Dosage and Administration (2.3) and Warnings and Precautions (5.1)]. WARNING: ADRENAL CRISIS IN THE SETTING OF SHOCK, SEVERE TRAUMA OR INFECTION See full prescribing information for complete boxed warning. Patients treated with LYSODREN are at increased risk for developing adrenal crisis in the setting of shock, severe trauma or infection that may lead to death. If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. Monitor patients closely for infections and instruct patients to contact their physician immediately if injury, infection, or any other concomitant illness occurs ( 2.3 , 5.1 ).

Renal impairment — from the label

LYSODREN is not recommended for patients with severe renal impairment. In patients with mild or moderate renal impairment, monitor mitotane plasma levels frequently and modify the dosage as needed. (8.7)

Kidney rows of the label's dosage tables

From the Lysodren label (Mar 2026) · DailyMed

No row of this label's dosage table names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.

What gets reported — FAERS

Everything below is FAERS — adverse events someone chose to report, about 1,830 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.

  • Reporting odds ratio (ROR) — is kidney injury named in this agent's reports more often than in every other drug's? Above 1 means yes, disproportionately.
  • Renal phenotypes — the same question asked separately for each kind of kidney injury, so the ratios differ from the overall one and from each other.
  • Outcomes — a share of this agent's own reports, not of patients: how many were filed as involving a death or a hospitalization. Not a case-fatality rate.
FAERS reported renal phenotypes· 2 signals

Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.

What reporting says about this profile's documented lesions

  • Electrolyte Disturbancereporting signal · ROR 5.14 — but the naming terms alone are not disproportionate, so this rests on terms merely consistent with the lesion
  • Prerenal / Hemodynamic AKINot queried in FAERS — No MedDRA term set is defined for this phenotype, so FAERS was never asked about it.
SIADH / Hyponatremia
ROR 6.3695% CI 4.78–8.48· 48 reports· IC025 2.12
Electrolyte Disturbance
ROR 5.1495% CI 4.17–6.35· 91 reports· IC025 1.96
FAERS outcomes & reporting trend· 13% of reports w/ death · 27.3% w/ hospitalization
13%

Reported with a death outcome

237 of 1,830 reports

27.3%

Reported with hospitalization

499 of 1,830 reports

Reports per year

  • 2015: 43 reports
  • 2016: 41 reports
  • 2017: 59 reports
  • 2018: 122 reports
  • 2019: 55 reports
  • 2020: 82 reports
  • 2021: 114 reports
  • 2022: 171 reports
  • 2023: 180 reports
  • 2024: 228 reports
  • 2025: 193 reports
  • 2026: 257 reports

Reports received per year, 2015–2026 · most recent year is partial · 285 of the 1,830 reports predate 2015 and are not drawn.

FAERS adverse-event signal — all organ systems· 8 systems · 1,830 reports

Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.

Disproportionality (acute kidney injury):ROR 0.9895% CI 0.63–1.54· 19 AKI reports· IC025 −0.75·no disproportionate AKI reporting signal (CI spans 1).
Renal & urinary
Adrenal Insufficiency134
Gastrointestinal
Nausea319Diarrhoea173Vomiting157Abdominal Discomfort39Constipation38
General / constitutional
Fatigue291Asthenia105Weight Decreased63Pyrexia45
Nervous system
Dizziness120Headache57Somnolence52
Blood & lymphatic
Neutropenia66Anaemia64Febrile Neutropenia52
Metabolic & electrolyte
Decreased Appetite117Hyponatraemia44
Skin
Rash46
Endocrine
Hypothyroidism35
Guidelines & consensus· 13

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Mitotane sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.
Phenotype-similar agents· the numbered markers on the map above

Octreotide

Sandostatin · Somatostatin analog

Profile

Kidney-neutral/possibly renoprotective; renally cleared, caution in severe CKD/dialysis.

LYTEPRE
Mild#1 · 93% phenotype match

Lanreotide

Somatuline · Somatostatin analog

Profile

Kidney-neutral (CLARINET: diarrhea dominant); increased exposure in renal impairment.

LYTEPRE
Mild#2 · 91% phenotype match

Darolutamide

Nubeqa · Androgen receptor inhibitor (ARSI)

Profile

Not nephrotoxic; exposure rises in severe renal impairment, so consider dose adaptation.

LYTEPRE
Mild#3 · 90% phenotype match

Strontium-89 chloride

Metastron · Bone-seeking radiopharmaceutical

Profile

Renally excreted, so caution in renal impairment; myelosuppression is the dominant toxicity.

LYTEPRE
Moderate#4 · 87% phenotype match

Neratinib

Nerlynx · HER2 / pan-EGFR TKI

Profile

Severe diarrhea → prerenal AKI; loperamide prophylaxis.

PRELYTE
Moderate#5 · 85% phenotype match

Glasdegib

Daurismo · Hedgehog (SMO) inhibitor

Profile

QT prolongation and muscle spasms; AML.

PRELYTE
Mild#6 · 79% phenotype match
Compare Mitotane with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.

Kidney risk across Hormonal / endocrine

Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.

  1. 1CamizestrantFAERS n/aMild
  2. 1ElacestrantMild
  3. 1LeuprolideMild
  4. 1VepdegestrantFAERS n/aMild
  5. 5DarolutamideMild
  6. 5EnzalutamideMild
  7. 5ImlunestrantMild
  8. 5LanreotideMild
  9. 5OctreotideMild
  10. 10TamoxifenMild
  11. 11BicalutamideFAERS AKIMild
  12. 12Mitotane· this agentModerate
  13. 13AbirateroneFAERS AKIModerate

A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.